We Innovate Healthcare

Our passion to improve lives is the driving force behind Roche Diagnostics’ innovation in the diagnostics industry. We develop and produce medical tests that provide information to assist medical decision makers in delivering the best patient care. Our products not only diagnose disease, they also monitor drug therapies to provide physicians with accurate information to ensure their patients are receiving the most effective treatment.

Roche stands out among its peers in its large investment in research and development, enabling it to provide diagnostics solutions. In 2006, we spent 9 percent of our global product sales, or $557 million, on research and development - more than any of our top six competitors.¹

As a global leader in diagnostics, we constantly work to improve our products and services. Our expertise in a variety of diagnostic technologies allows us to introduce innovative products that shape new markets and take diagnostics into new dimensions. This expertise and a global presence help Roche Diagnostics respond quickly to a variety of global health issues. We also have a broad portfolio of diagnostics tools for congestive heart failure, HIV, hepatitis B and C, fertility testing, diabetes and many other diseases. This wide array of innovative testing products and services is supplied to researchers, physicians, patients, hospitals and laboratories worldwide.

Roche Diagnostics focuses on actionable health information. Actionable health information takes information from multiple diagnostic sources and translates it into data that helps our customers (laboratories, researchers, physicians and patients) to make informed decisions about prevention or therapy. Providing the right tools and the right information are the future in healthcare, and Roche Diagnostics is on the cutting edge, integrating information for a comprehensive, actionable healthcare solution.

Roche Diagnostics is a world diagnostics leader and holds top leadership positions in:

• diabetes care
• centralized diagnostics
• point-of-care testing
• NAT blood screening
• molecular diagnostics

Indianapolis – North American Headquarters

The Roche Diagnostics Indianapolis campus is home to U.S. research and development, laboratory, manufacturing, distribution, information technology and corporate headquarters operations, in support of five diagnostics business areas: Diabetes Care, Centralized Diagnostics, Applied Science, Molecular Diagnostics and Point of Care.

OUR AREAS OF EXPERTISE:

Applied Science is one of the world’s leading producers of instrument and reagents (chemicals) for life science research. Our particular focus on genomics and proteomics had led to the creation of the LightCycler^® instrument for real-time polymerase chain reaction (PCR) research and the Genome Sequencer System for ultra-fast genome sequencing.

Centralized Diagnostics provides integrated, high-performance analytical systems to optimize laboratory management from pre-analytical to post-analytical processes. We develop high quality solutions for diagnostics laboratories - from analyzers and test reagents to work-flow solutions. To maintain its leadership in technology and quality, Roche minimizes third party products with more than 75 percent of its assay portfolio developed and manufactured in-house.

Diabetes Care is the world leader and a pioneer in innovating blood glucose monitoring systems. We are committed to delivering solutions that meet the needs of people with diabetes and their healthcare professionals. The ACCU-CHEK^® brand helps complete the circle of care by providing products, services and support needed to help people better manage their diabetes. ACCU-CHEK® products include blood glucose meters, lancets, test strips, insulin pump systems, infusion sets and supplies, and data management tools.

Molecular Diagnostics focuses on developing predictive tools that can assist in patient prognosis and treatment. Our portfolio is based on polymerase chain reaction (PCR) technology - the world’s leading nucleic acid amplification testing (NAT) technology - and applies clinical diagnostics in six key areas: virology, women’s health, microbiology, blood screening, genomics and oncology. PCR has provided the basis for unprecedented advances in the diagnosis and monitoring of life-threatening diseases, such as HIV and hepatitis and as an aid in genetic identification. We also produce highly sensitive blood screening applications that assist in safeguarding the nation's blood, organ and tissue supply.

Point of Care provides diagnostics methods employed by medical professionals at the "point of care" in any operating theater: intensive-care area, ambulance, surgery suite, blood bank, primary care physician’s office or cardiologist’s office and pharmacy. Point-of-care testing offers rapid, easy-to-use diagnostics tools, such as small, portable benchtop analyzers for a variety of applications. We market the CoaguChek^® system, the leading instrument for monitoring patients on Coumadin^® therapy.

ROCHE DIAGNOSTICS, NORTH AMERICA, LOCATIONS:

OUR INDIANAPOLIS HISTORY:

Within three years of Roche Diagnostics' 1998 acquisition of Boehringer Mannheim Corporation, we grew to become the world diagnostics leader in producing innovative products, the depth and breadth of our technologies and our overall geographic presence.

Since its founding in Indianapolis in 1964 as Bio-Dynamics (later acquired by Boehringer Mannheim in 1974), Roche Diagnostics has grown tremendously. Today, we have about 3,700 employees in Indianapolis. Our campus is made up of 150-acres and houses 18 buildings with more than 1.3 million square feet of space in Marion and Hamilton counties.

Since our beginning, Roche Diagnostics has grown to be a viable force in developing Indiana's life sciences initiative.

Roche Diagnostics Corporation

Roche Diagnostics Operations, Inc.
9115 Hague Road
Indianapolis, Indiana 46205
317-521-2000
www.roche-diagnostics.us

OUR GLOBAL PRESENCE:

Headquartered in Basel, Switzerland, The Roche Group is one of the world’s leading innovation-driven healthcare groups with its core businesses of pharmaceuticals and diagnostics. Roche is No. 1 in the global in-vitro diagnostics market,2 the leading supplier of pharmaceuticals for cancer, and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Roche Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche employs approximately 70,000 people worldwide in 150 countries.

¹$557 million is the amount Roche Diagnostics spent in 2006 on research and development in the "Roche Annual Report 2006" compared with its six main competitors Abbott, J&J, Beckman, Bayer and Dade. All figures for competitors taken from research and development global spending figures for 2006 from BBC Market Book.

² Boston Biomedical Consultants and company reports